Sponsorship Agreement

1 Parties

The signor

Merck Sharp & Dohme (Sweden) Aktiebolag, Reg. No. 556187-0014

("MSD")

and the co-signor

Mediahuset i Göteborg AB Reg. No. 556483-2862

(the "Organisation")[1]

(MSD and the Organisation are collectively referred to as the "Parties" and individually a "Party".) have concluded the following sponsorship agreement (the "Sponsorship Agreement").

[1] Linklaters note: depending on who MSD enters into the sponsorship agreement with different sections in LER will apply. If the sponsorship agreement is entered into with the actors within the healthcare sector chapter 2 in LER will apply and if the sponsorship agreement is entered into with organisations and politicians chapter 3 in LER will apply. For the purpose of this agreement organisations within LER mean interest organisations which form opinion within the healthcare sector, such as the Swedish Cancer Society, the Swedish Heart- Lung Foundation etc.

2 Purpose of Sponsorship Agreement

The purpose of the Sponsorship Agreement is the organisation of Mediahuset i Göteborg Aktiebolag will organize the IBD Nordic Conference and MSD will be one of the sponsors. The meeting is aimed at healthcare professionals within the field of gastroenterology.

3 Name of collaborative project

The name of the collaborative project is **IBD Nordic Conference 2026.**

4 Parties' roles in relation to sponsorship

By way of this Sponsorship Agreement and during the term hereof, MSD undertakes to:
Sponsor the IBD Nordic Conference 2026.

By way of this Sponsorship Agreement and during the term hereof, the Organisation undertakes to:

Arrange the IBD Nordic Conference 2026.

5 Time frame

The sponsorship, the specific purpose and scope of which are described in clauses 2 and 4, runs from **2026-11-25** to **2026-11-27** at Quality Hotel View, Malmö Sweden. The Parties' rights and obligations under the Sponsorship Agreement run from the date the agreement is executed and until the obligations of the Sponsorship Agreement have been performed unless otherwise explicitly agreed. The Parties will continuously reconcile and evaluate the sponsorship to ensure that it proceeds as agreed by the Partiers. The Parties will evaluate the sponsorship after it has been completed.[2]

6 Financial commitment

MSD's financial commitment under the Sponsorship Agreement will be in the amount of SEK **64 000**, exclusive of VAT. The financial commitment must be used for:

- Showcase in the exhibition area: 1 x 1 m
- Standing tables included: 1
- No. of staff members included: 2
- Discounted conference fee for HCP participants
- Logotype in all advertisements, conference material & conference website

The Organisation must send the invoice to MSD together with documentation for the costs incurred which MSD's financial commitment is to cover, and MSD is entitled to refuse to cover any costs that are not in accordance with the Sponsorship Agreement and the codes of ethics applicable to a pharmaceutical company such as MSD, including without limitation chapter 2 section 5 Ethical Rules for The Pharmaceutical Industry in Sweden (“LER”).

Pharmaceutical companies may not offer sponsorship to a sum exceeding the cost of the professional improving activity/conference. Professional improvement does not include for example entertainment, expensive meals, or travel and lodging for participants.

The Organisation shall provide in Exhibit 3 a detailed program and the budget estimate for the activity to MSD for decision making purposes.

The Organisation shall, within 3 months of the completion of the activity, report the final detailed financial outcome of the activity to the contact person at MSD. If net result is positive for the scientific part of the activity, the exceeding part should, as a general rule, be refunded to the sponsors

[2] Linklaters note: the wording regarding the parties obligation to reconcile and evaluate the sponsorship is only necessary if the sponsorship agreement is entered into with organisations and politicans.

MSD is entitled to request that the Organisation provide documentation for how the support has been used, including by presenting accounts for all income and expenses relating to the project.

Payment.

Payment is made through sent invoice and should be sent to address: MSD Att: Susanna Larsson susanna.larsson@msd.com Box 45192, 104 30 Stockholm.
Please note that MSD cannot pay to Plusgiro and payment terms is maximum 90 days.

Organisation or Hospital Organisation	
Name	Mediahuset I Göteborg AB
Organisation no:	556483-2862
Bankgiro Nr/Bank Account No:	444-0715

7 Non-financial commitment

MSD shall not have any non-financial commitment.

8 Other conditions for the sponsorship

As a pharmaceutical company, MSD is subject to several obligations where MSD's commitments under the Sponsorship Agreement are used by the Organisation for activities for healthcare professionals, including without limitation scientific events in the form of professional courses, conferences, professional development training, etc.

Specifically, the following obligations appear from chapter 2 sections 2a, 2b and 2.1,3 and 5. The event must not take place outside Sweden unless it makes significantly more logistical sense to hold the event in another country because most of the event participants come from abroad or because of the location of the relevant resource or expertise, which is the subject matter or topic of the event, see chapter 2 section 2b LER.

- Hospitality offered in connection with the event must be limited to travels, meals, accommodation and genuine registration fees, see chapter 2 sections 2b and 5 LER.
- MSD may only offer hospitality to persons who qualify as participants in their own right, see chapter 2, section 2b LER
- MSD must keep all forms of hospitality offered to healthcare professionals at a "reasonable" level and strictly limited to the main purpose of the meeting, which e.g. includes being equal in duration to the promotional or scientific event, see chapter 2 article 2a LER
- MSD must not provide or offer meals (food and beverages) to healthcare professionals, except in cases where the value of such meals does not exceed the following caps: SEK 350 (including VAT) for lunch, SEK 950 (including VAT) for dinner see LIF definitions of terms and values in relation to the EFPIA:s Code and IFPMA Codes of Practice. The said caps apply to meals in Sweden.
- Hospitality must not include sponsorship or organisation of entertainment events, see chapter 2 section 2b LER.

- MSD must avoid using venues, which are "known" for their entertainment facilities, are extravagant and/or luxurious, see chapter 2 section 2b LER

- MSD must not offer funding to compensate for the time spent by healthcare professionals in attending the scientific events and participants are not entitled to receive or request remuneration for their participation, see chapter 2 section 5 LER

- Anyone who participates in a meeting is responsible for obtaining the employer's approval for participation, chapter 2 section 2b LER.

By way of the Sponsorship Agreement, the Organisation undertakes to ensure that the above obligations to which MSD is subject are met in connection with the project sponsored by MSD under the Sponsorship Agreement. Moreover, MSD's sponsorship is not subject to MSD influencing the scientific contents of the event, its lecturers, educational methods, etc.

The Parties agree that the Sponsorship Agreement does not constitute an inducement or payment to recommend, prescribe, purchase, supply, sell or administer specific medicinal products or other products or services from MSD.

When distributing invitations to events sponsored by MSD under the Sponsorship Agreement, the Organisation must ensure that it is stated on such invitations that the events are sponsored by MSD (and other pharmaceutical companies, if relevant). This also applies to other written material concerning the events. The Organisation must also ensure that scientific events are conducted separately from any professional events, including e.g. exhibition stand, where pharmaceutical companies are given the opportunity to promote medicinal products. The Organisation must also ensure that the events are inaccessible to the general public.

The Organisation is generally obligated to comply with any current, relevant legislation, e.g. by ensuring compliance with the Swedish Penal Code on bribery in respect of the events sponsored by MSD under the Sponsorship Agreement.

[As a pharmaceutical company, MSD is, pursuant to the Ethical Rules for the Pharmaceutical Industry in Sweden (Läkemedelsbranschens etiska regelverk) required to notify the sponsorship with the Organisation to the cooperation database (www.lif.se)][3]

9 Contacts

MSD's contact person in respect of the Sponsorship Agreement is: Eva Lindgren
eva.lindgren@msd.com +46 (70) 9351950

The Organisation's contact person in respect of the Sponsorship Agreement is: Niklas Lundblad
niklas@mediahuset.se

10 Use of Organisation's logo

The Organisation does not agree to MSD's use of the Organisation's logo or name or any other use of the sponsorship with the Organisation.

11 MSD material

Material provided by MSD to the Organisation in connection with the sponsorship, see clauses 2 and 4 (the "MSD Material"), will remain MSD's property. The Organisation is obligated without exception to return all the MSD Material to MSD and destroy all copies thereof made by the Organisation at MSD's written request and immediately after completion of the Services at his/her own initiative, see clauses

[3]Linklaters note: Reporting obliation for MSD depending on type of organisaiton (if health care related, including patient organisations) reporting is required.

2 and 4. The Organisation will never be entitled to withhold any of the MSD Material from MSD, irrespective of the cause.

The Organisation agrees to ensure that all audience members present during the MSD presentation and any associated presentation video are authorized to hear the content of said presentation. By signing this agreement, the Organisation confirms that the audience is permitted to access and engage with the content delivered in the MSD presentation and presentation video.

12 Intellectual property rights

Unless expressly authorised in writing by the other Party or set out herein, neither Party is entitled to use the other Party's intellectual property rights, including all adaptations and variations thereof and amendments thereto for any purpose.

All intellectual property rights belonging to a Party before the effective date created by or for a Party independently of the Sponsorship Agreement, remain vested in that Party.

12.1 If the Organisation's/ Professional Congress Organisation´s services include the Organisation's/ Professional Congress Organisation´s creation or development of deliverables for MSD, the rights to such deliverables, including to any intellectual property rights embedded therein, will fully and solely vest in MSD. In that regard, the Organisation/ Professional Congress Organisation acknowledges that all intellectual property rights subsisting (or which may subsist in the future) in such deliverables, if any, will automatically fully vest in MSD on creation. To the extent that they cannot automatically vest in MSD, the Organisation/ Professional Congress Organisation agrees to assign and transfer all rights, title and benefits relating to such intellectual property rights to MSD. The Organisation/ Professional Congress Organisation agrees to promptly execute all documents and perform all acts as may, in MSD's opinion, be necessary to give effect to this clause. To the extent permitted by law, the Organisation/ Professional Congress Organisation hereby irrevocably waives all moral rights (and all similar rights in other jurisdictions) which MSD has or will have in any such deliverables created or developed by the Organisation/ Professional Congress Organisation for MSD.

12.2 To the extent that any deliverables include any intellectual property rights belonging to the Organisation/Professional Congress Organisation, the Organisation/ Professional Congress Organisation hereby grants to MSD and/or its affiliates a royalty-free, worldwide, exclusive, non-transferable, irrevocable licence to use such intellectual property rights.

13 Confidentiality

The Organisation/Professional Congress Organisation must, to the extent permitted under Swedish law, keep confidential all information about MSD, MSD's business activities and the sponsorship in connection with the Sponsorship Agreement, see clauses 2 and 4, which the Organisation/Professional Congress Organisation obtains before, during or in connection with the sponsorship, including without limitation the Sponsorship Agreement, the MSD Material and created material ("Confidential Information"). Confidential Information does not include any information being or becoming available to the public unless such availability is due to the Organisation's/Professional Congress Organisation´s breach of the duty of confidentiality.

14 Independence and impartiality

By signing the Sponsorship Agreement, the Parties declare that the Organisation/Professional Congress Organisation is free to collaborate with several pharmaceutical companies and that MSD is also free to collaborate with one or more organisations. The Parties further declare that the sponsorship will not require exclusive rights with respect to specific product or therapeutic areas.

14.1 By signing the Sponsorship Agreement, MSD declares not to impose conditions on the Organisation´s /Professional Congress Organisation´s stand on professional, scientific and political issues.

14.2 By signing the Sponsorship Agreement, MSD declares not to hold a position of trust within the Organisation/Professional Congress Organisation of importance to the Sponsorship Agreement.

The Organisation/Professional Congress Organisation undertakes to disclose to MSD without delay any and all circumstances existing at the time of signing of the Sponsorship Agreement or arising at any time during the term hereof and involving the Organisation/Professional Congress Organisation or any of its directors, officers or members of their respective families, or any of its employees engaged in the supply of the goods and services hereunder or members of their respective families, which may constitute a conflict of interest for the business relationship between the Parties. In the event of a conflict of interest, the Organisation/Professional Congress Organisation must cease to work for MSD if requested to do so by MSD.

15 Breach

If one of the Parties breaches its obligations under the Sponsorship Agreement, the non-breaching Party may terminate the Sponsorship Agreement with immediate effect. The non-breaching Party will also be entitled to seek other remedies for breach available under Swedish legislation, including the right to claim damages, irrespective of whether the Sponsorship Agreement is terminated for breach.

15.1 MSD's company policy requires that MSD's business and operations comply with legislation applicable to MSD's business area. The Organisation/ Professional Congress Organisation accepts to comply at all times with MSD's Ethical Business Practice Policy and Code of Conduct enclosed as **Exhibit 1** to the Sponsorship Agreement. If the Organisation or any third party acting on behalf of the Organisation fails to comply with the provisions of **Exhibit 1**, it will be deemed to be a material breach of the Sponsorship Agreement. In such cases, MSD may terminate the sponsorship Agreement with immediate effect subject to written notice to the Organisation/ Professional Congress Organisation, and the Organisation/ Professional Congress Organisation must indemnify MSD in respect of any liability resulting from the Organisation's/ Professional Congress Organisation’s neglect.

16 Data protection

The processing and protection of personal data in connection with the Sponsorship Agreement is described in **Exhibit 2**, which the Parties agree to have read and accepted by signing the Sponsorship Agreement.

17 Governing law and jurisdiction

The Sponsorship Agreement is subject to Swedish substantive law in every respect. If disputes cannot be resolved by mediation, they must be brought before the District Court of Stockholm.

18 Signatures

For MSD:	For the Organisation:
Sep 29, 2026	sep 29, 2026
Date:	**Date:**
Tomas Täckström	Niklas Lundblad
Printed Name:	**Printed Name:**
Signed by Tomas Täckström Tomas Täckström | I approve this document Sep 29, 2026 | 12:06:57 PM **Signature**: Medical Director Sweden 9E58B997F462406C94CD99F1B6998E4D	Signed by Niklas Lundblad Niklas Lundblad | Jag godkänner dokumentet Sep 29, 2026 | 5:23:36 AM MDT **Signature:** Head of Marketing 8919D61F24B64458B4BCDB709C3B14944D

Exhibit 1: Ethical Business Practice Policy and Code of Conduct

In performing its obligations under the Sponsorship Agreement, the Parties acknowledge that the corporate policy of MSD and its affiliates requires that MSD's business be conducted within the letter and spirit of the law. By signing the Sponsorship Agreement, the Parties agree to conduct the business contemplated herein in a manner which is consistent with applicable legislation, including the U.S. Foreign Corrupt Practices Act and good business ethics as described in this exhibit and as communicated to the Organisation by MSD or one of its affiliates from time to time. Specifically, the Organisation warrants and agrees that, in connection with the Sponsorship Agreement and MSD's business relating thereto, it, its affiliates, their representatives and anyone acting on their behalf will not offer, make or promise any payment, neither directly nor indirectly, of money or other things of value (collectively, "**Payment**") to any government, political party or international organisation, official, candidate or person acting on behalf of any of the foregoing or directly associated with them, including their employees, business partners, close associates and families (collectively, "**Officials**"), where such Payment would constitute a violation of applicable legislation. In addition, regardless of legality, the Parties must not make any Payment, neither directly nor indirectly, to Officials if such Payment is for the purpose of improperly influencing decisions or actions with respect to the subject matter of the Sponsorship Agreement or the business activities of MSD or its affiliates. The Organisation must indemnify MSD for and against all claims, liabilities, demands, losses, fines and penalties resulting in any way from the failure of the Organisation to comply with this exhibit.

The Organisation represents and warrants to the best of its knowledge that the Organisation and its affiliates have provided complete and accurate information and documentation to MSD, its affiliates and their representatives in the course of any due diligence that was conducted, including disclosure of any officers, employees, owners or persons directly or indirectly retained by the Organisation who are in a capacity that may reasonably provide an opportunity to influence decisions or actions with respect to the subject matter of the Sponsorship Agreement or the business activities of MSD or its affiliates. The Organisation also acknowledges and agrees that, in the event that the Organisation engages an affiliate, subcontractor or agent, the Organisation will conduct due diligence on such affiliate, subcontractor or agent consistent with the requirements set out in this exhibit and will maintain adequate records and provide such records to MSD to evidence that such due diligence was conducted and that any identified risks were mitigated. The Organisation must make all further disclosures as necessary to ensure that the information provided remains complete and accurate for the duration of the term. The Organisation further covenants that any future information and documentation submitted as part of further due diligence or a certification will be complete and accurate to the best of its knowledge.

The Organisation represents, warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under the Sponsorship Agreement, or any statement of work are and will be complete and accurate and reflect in reasonable detail the nature and amounts of transactions and expenditures.

The Organisation further represents, warrants and agrees that no "**off the books**" or other similar funds will be maintained or used in connection with the Sponsorship Agreement or any statement of work. Except as expressly provided for in the Sponsorship Agreement, the Organisation must not, without MSD's prior written consent which must not be unreasonably withheld, hire or retain subcontractors or agents who will be interacting with Officials on behalf or at the request of the Organisation and who may have an opportunity to influence decisions or actions with respect to the subject matter of the Sponsorship Agreement or any statement of work or the business activities of MSD or its affiliates.

The Organisation agrees to ensure that all of the Organisation's and its affiliates' representatives, agents and subcontractors involved in performing the obligations under the Sponsorship Agreement are made specifically aware of the compliance requirements under this exhibit, including without limitation by participation of such personnel, employees, agents and subcontractors in mandatory training to be conducted by the Organisation concerning such requirements prior to performing any obligations under the Sponsorship Agreement. The Organisation further agrees to certify its continuing compliance with the requirements under this exhibit on a periodic basis during the term of the

Sponsorship Agreement in such form as reasonably required by MSD. The Organisation agrees to and will cause its personnel or subcontractors to implement and/or sustain a compliance programme to comply with the requirements of this exhibit and to maintain adequate records of such compliance programme.

MSD endeavours to hold itself and the Organisation to the highest ethical and compliance standards, including basic human rights, encouraging fair and equal treatment for all persons, the provision of safe and healthy working conditions, respect for the environment, the adoption of appropriate management systems and the conduct of business in an ethical manner. Without limiting any of the Organisation's other obligations hereunder and without conflicting with or limiting any of the warranties, obligations or other provisions expressly set out elsewhere in the Sponsorship Agreement, including without limitation its obligations under this exhibit, the Organisation agrees that it will abide by the letter and spirit of MSD's Business Partner Code of Conduct (the "**Code**") as in effect from time to time, a copy of which is available at http://www.msd.com/about/how-we-operate/code-of-conduct/home.html. In the event of a conflict between the obligations in this exhibit and MSD's Code of Conduct, on the one hand, and any other provision in the Sponsorship Agreement, on the other hand, such other provision of the Sponsorship Agreement will prevail (but only to the extent of the conflict).

The Organisation agrees that it will provide all documentation reasonably requested by MSD to demonstrate compliance with the Code.

MSD reserves the right, in its sole discretion, to audit the Organisation's operations, books and records to ensure compliance with this exhibit for a period of two years following termination and/or expiry of the Sponsorship Agreement. MSD will provide reasonable advance notice of such audit and may conduct it on its own or using a third-party auditor of its choosing. The Organisation must acknowledge MSD's notice as promptly as practicable after receipt of such notice and will confirm the date on which the audit will occur within 14 days after receipt of such notice. MSD or its third-party auditor may interview the Organisation's employees as part of or in connection with the audit. This audit right is in addition to any other audit rights granted under the Sponsorship Agreement.

In the event that an audit identifies any non-compliance by the Organisation with this exhibit, the Organisation will promptly take corrective action to remedy such non-compliance. MSD reserves the right to approve all corrective actions. Corrective actions must be implemented by the Organisation at the Organisation's expense. MSD will endeavour, whenever practicable, to work with the Organisation to remedy the issue and put in place a corrective action plan.

In the event that the Organisation refuses to allow an audit or fails or refuses to take corrective action, MSD reserves the right to terminate the Sponsorship Agreement if the Organisation fails to cure such refusal or failure within 90 days after written notice from MSD. This right is in addition to any other remedy available to MSD under the Sponsorship Agreement, legislation or case law.

Without prejudice to any rights of MSD under the Sponsorship Agreement, any non-compliance with, or any breach of a representation or warranty set out in, this exhibit will constitute a material breach of the Sponsorship Agreement, and, in that case, MSD may terminate the Sponsorship Agreement immediately without payment of penalty or damages or further performance of any kind.

Exhibit 2: Processing and protection of personal data

Each Party must, at its own expense, ensure that it complies, and cause the other Party to comply, with all statutory and regulatory requirements in force from time to time relating to the use of personal data and the privacy of electronic communications, including the Data Protection Legislation (as defined below).

Definitions

"**Data Protection Legislation**" means any data protection, data security or privacy legislation including, without limitation, the EU General Data Protection Regulation 2016/679 (the "**GDPR**") and any national implementing legislation relating thereto and any legislation governing outbound telephone calls, transmission of electronic mail, transmission of fax messages and any other communication-related data protection, data security or privacy legislation, to which either Party is subject in connection with the Sponsorship Agreement.

"**Personal Data**" means any data relating to an identified or identifiable individual, including data that identifies an individual or that could be used to identify, locate, track or contact an individual. Personal Data includes both directly identifiable information, such as names, identification numbers or unique job titles, and indirectly identifiable information, such as dates of birth, unique mobile or wearable device identifiers, information that could be used to identify a household, telephone numbers, key-coded data or online identifiers, such as IP addresses, and includes any data that constitutes "personal data" under the GDPR or similar terms under other Data Protection Legislation.

"**Process**" means to perform any operation or set of operations on Personal Data or sets of Personal Data, whether or not by automatic means, such as collection, recording, organisation, structuring, storage, access, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, evaluation, analysis, reporting, sharing, alignment or combination, restriction, erasure or destruction.

In the event that the definitions in this exhibit are inconsistent with the definitions given to similar terms or concepts under Data Protection Legislation, the definition given to any such similar term or concept under that applicable Data Protection Legislation will prevail to the extent of the inconsistency, so long as such inconsistency results in a broader definition of such term or concept.

Data Protection Legislation; Notices, Consent and Authorisations.

The Organisation must comply with Data Protection Legislation when performing its obligations under the Sponsorship Agreement, including without limitation when Processing any Personal Data.

The Organisation represents and warrants that:

(A) with respect to any Personal Data Processed under the Sponsorship Agreement, except for Personal Data for which MSD is responsible under Data Protection Legislation for giving and obtaining the notices and consents, at the original time of collection of that Personal Data, necessary for Processing (so long as the Parties do not agree for the Organisation to be responsible), (i) all notices will have been given and the Organisation has and will maintain in effect during the Sponsorship Agreement all consents, approvals, authorisations and rights necessary to Process any such Personal Data, including without limitation sharing any Personal Data with MSD, its affiliates or their respective agents or representatives, for any of them to use such Personal Data as contemplated in the Sponsorship Agreement and for any regulatory purposes, and (ii) the Organisation will Process such Personal Data only in accordance with any such notice, consents, approvals and authorisations.The Organisation will Process Personal Data in connection with the Sponsorship Agreement only where it is lawful.

Exhibit 3: Budget Estimate and Program

PRELIMINARY BUDGET

IBD Nordic 2026

Sponsorable costs	#	Unit price (SEK)	Total (SEK)
Conference venue			541 000 kr
Technical equipment			199 500 kr
Lunch,	350	310 kr	108 500 kr
Coffee and snacks	1200	150 kr	180 000 kr
Conference dinner	350	840 kr	294 000 kr
Congress material	400	250 kr	100 000 kr
Speakers fees	17	12 500 kr	212 500 kr
Speakers & moderators travel/accomodation expenses	20	15 000 kr	300 000 kr
Staff, Security, Technicians	15	12 000 kr	180 000 kr
Advertisement & Invitations			250 000 kr
Conference Website			100 000 kr
Administration	1	240 000 kr	240 000 kr
Total			**2 705 500 kr**

Costs covered with participation fees	#	Unit price (SEK)	Total (SEK)
Chariman compensation	2	16 000 kr	32 000 kr
Staff travel & accommodation	10	10 000 kr	100 000 kr
Decorations			40 000 kr
Poster Award Scholarship	1	25 000 kr	25 000 kr
Planning meetings Steering committee			30 000 kr
Travel/accommodation Steering committee	15	12 500 kr	187 500 kr
Mingle	400	580 kr	232 000 kr
Pre-conference dinner			48 000 kr
Total			**694 500 kr**

Income	#	Unit price (SEK)	Total (SEK)
Gold Exhibitors	6	235 000 kr	1 410 000 kr
Satellite Symposium	6	50 000 kr	300 000 kr
Silver Exhibitors	3	140 000 kr	420 000 kr
Bronze Exhibitors	6	85 000 kr	510 000 kr
Participation fees	190	4 000 kr	760 000 kr
Total income			**3 400 000 kr**

Please note that no remuneration is paid to the HCO at this meeting. Neither is there a share of any profit, which is entirely for the benefit of Mediahuset.

The meeting is arranged in accordance with the LER with regard to program content, social activities, cost of meals, lecturer fees, etc. The sponsors cannot influence the scientific program, which is determined exclusively by the lecturers/moderators.

Mediahuset i Göteborg AB
Marieholmsgatan 10C
(+46)31 – 797 27 80
event@mediahuset.se

Preliminary Program

Wednesday	Session / Talk	Speakers / Moderators
13.00 – 13.30	**Opening Session**	
10m	Welcome	
20m	Honorary speaker: Transition of IBD over 30 years	Kaija Leena Kolho (Finland)
13.30 – 14.30	**Session 1: Looking into the future**	
20m + 10m Q&A	Future research in the Nordics	Jonas Ludvigsson (Sweden)
20m + 10m Q&A	What's in the Pipeline? TL1A and other emerging drugs	Krisztina Gecse (UK)
14.30 – 15.00	Break	
15.00 – 16.30	**Session 2: Treating Fribrosis**	
20m + 10m Q&A	Everything you need to know about fibrosis	Florian Rieder (USA)
20m + 10m Q&A	Practical Endoscopic Management of Strictures in Crohn's Disease	Marc Ferrante (Belgium)
20m + 10m Q&A	Saving bowel - to what length?	Maria Hermansson (Sweden)
16.30 – 17.00	Poster Break 1	*Make sure to visit the posters during this break! Authors are kindly asked to be present by their posters*
17.00 - 18.10	**Satellite symposia session**	
17.00 - 17.30	**Satellite symposia 1**	
20m + 10m Q&A		
17.30 – 17.40	Short Break	
17.40 - 18.10	**Satellite symposia 2:**	
20m + 10m Q&A		
18.10 – 19.30	Mingle & Quiz in the exhibition hall	
18.40 – 19.30	**Poster Presentations**	
	8 selected posters presented orally in the poster presentation room	

Thursday 26/11	Session / Talk	Speakers / Moderators
09.00 - 09.30	**Satellite symposia session**	
09.00 - 09.30	**Satellite symposia 3:**	
20m + 10m Q&A		
09.30 – 09.40	Short Break	
09.40 – 12.10	**Session 3: Future burden of IBD**	
20m + 10m Q&A	Accumulating Success: The Reality of Compounding Prevalence	Johan Burisch (Denmark)
20m + 10m Q&A	What should we do - Stride 3	Axel Dignass (Germany)
10.40 - 11.10	Break	
20m + 10m Q&A	Real life implications. What do we do?	Panel:
		Lone Larsen (Denmark)
		Marte will find a norwegian?
		Loa will find a name for Iceland
		Daniel Bergmalm (Sweden)
		Miko Mattilla (Finland)
20m + 10m Q&A	How does this connect to the outcome of the e-quality project?	Gionata Fiorino (Italy)
12.10 - 13.00	Lunch	
13.00 - 14.00	**Session 4: Reshaping the IBD team**	
20m + 10m Q&A	Expanding the IBD-Nurse role - the N-ECCO Consensus Statement	Simona Radice (Italy)
20m + 10m Q&A	The Nurse Endoscopist: Expanding the Scope of Screening and Education	Oskar Almqvist (Sweden)
14.00 - 14.30	**Oral Presentations**	
4min talk + 2 Q&A	TBD	
4min talk + 2 Q&A	TBD	
4min talk + 2 Q&A	TBD	
4min talk + 2 Q&A	TBD	
14.30 - 15.00	Poster Break 2	*Make sure to visit the posters during this break! Authors are kindly asked to be present by their posters*
15.00 - 16.30	**Session 5: Comorbidities**	
20m + 10m Q&A	Treatment or Diseas? Malignancies in IBD (iCare)	Julien Kirchgesner (France)
60m	MDT 1: The comorbid patient	Panel TBD
	Cardiovascular	*Gastro, Surgery, Nurse, Dietician*
	Osteoporosis	
	Diabetes?	
16.30 – 17.00	Break	
17.00 - 18.10	**Satellite symposia session**	
17.00 – 17.30	**Satellite symposia 4:**	
20m + 10m Q&A		
17.30 – 17.40	Short Break	
17.40 – 18.10	**Satellite symposia 5:**	
20m + 10m Q&A		
18.10 – 19.30	**Quiz & Mingle**	
20.00 - 22.00	**Conference Dinner**	

Friday 27/11	Session	Talk
08.30 – 09.50	**Satellite symposia session**	
08.30 - 09.00	**Satellite symposia 6**	
20m + 10m Q&A		
09.00 - 09.10	**Short Break**	
09.10 – 09.40	**Satellite symposia 7**	
20m + 10m Q&A		
09.40 - 09.50	**Short Break**	
09.50 – 11.20	**Session 6: Perianal treatment**	
20m + 10m Q&A	Background on Surgical management	Phil Tozer (UK)
20m + 10m Q&A	Medical management	Ignacio Catalan (NO)
20m + 10m Q&A	Stem Cell Therapy for Perianal Crohn's: Current Evidence and Future Horizon	Lilli Lundby (Denmark)
11.20 – 11.50	**Break**	
11.50 - 13.10	**Session 7**	
60m	MDT2 on Perianal	Panel:
		Phil Tozer,
		Krisztina Gecse (UK)
		Lilli Lundby (DK)
		Stoma-Nurse?
		Magnus tengvar (Radiology)
20	Closing	
13.10	**Adjourn followed by a take-away lunch**	

MSD Corporate Branding Permission Form

Thank you for your interest in MSD.

In follow up to your recent request, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA ("the Company") is providing this form for submission and evaluation of your request to grant you permission to use/reproduce the MSD Logo, (hereinafter "the Trademark"), as depicted on Exhibit A to be used for the specific purpose attached at Exhibit B ("Approved Use"), and to ensure the adherence to our quality control standards.

In consideration of this grant, please acknowledge you accept the following conditions and limitations:

1. The Trademark will be used solely in connection with the Approved Use, outside the U.S. or Canada.
2. You shall have no right to sublicense the use of the Trademark.
3. You shall not take any action that is inconsistent with the Company's ownership of the Trademark, and all goodwill and benefits accruing from the use of the Trademark shall inure to the benefit of the Company.
4. You waive any cause of action or right of indemnification against, and agree to hold harmless the Company, its successors or assigns from any claims, liability or damages arising out of your use of the Trademark.
5. The Trademark must be used in compliance with this Corporate Branding Permission to ensure compliance with our quality control requirements. If the Trademark is not used in compliance with this permission or if it is used to denigrate the Company or its products, this permission will immediately be revoked.
6. This permission is valid for a period of one (1) year from the date this request is approved by MSD and may be renewed in one- year increments upon a prior request in writing.

In order to confirm your acceptance of these conditions and our approval, please sign electronically and email to **BrandingGuide@merck.com.** A mock-up of the design/use in situ is also required for final approval.

Notification of approval determination will be sent via email.

ACKNOWLEDGED AND ACCEPTED: Signed by Niklas Lundblad

Signature: Niklas Lundblad Jag godkänner dokumentet Sep 29, 2026 | 5:23:41 AM MDT
Name: Niklas Lundblad
Organization: Mediahuset i Göteborg AB 3910D6124B644934BCDB709C3B14944D
Title: Head of Marketing
Date: sep 29, 2026

Attachment

MSD Corporate Branding Permission Form

EXHIBIT A

EXHIBIT B

To properly evaluate your recent request to use/reproduce the MSD Logo, please complete the form below, providing as much information as you can.

Date of request	2026-09-28
Name of organization or entity that will use the MSD Logo	Mediahuset i Göteborg AB
Contact person, phone number, email address	Niklas Lundblad niklas@mediahuset.se
Indicate why you would like to use the MSD Logo	MSD is a sponsor of The IBD Nordic Conference 2026 and the sponsorship package include logotype placement in all advertisements, conference material & conference website.
Describe the scope and context of how and where the MSD Logo will be used, including type of media (e.g., press release, website, promotional item), name of event/congress, etc. A mock-up of the design/use in situ is also required for final approval.	Logotype placement in all advertisements, conference material & conference website. https://ibdnordic.se/
Length of time of proposed use (no longer than 1 year)	1 Year
Country in which the MSD Logo will be used	Sweden

Certifikat om färdigställande

Kuvert-ID: 26612E3C-36F5-8859-8020-4BF9B38A5A84
Ämne: Complete with Docusign: Sponsorship Agreement IBD Nordic 2026.pdf
Källkuvert:
Dokumentsidor: 16
Certifikatsidor: 4
AutoNav: Aktiverat
Kuverterad stämpling: Inaktiverat
Tidszon: (UTC-05:00) Eastern Time (US & Canada)

Signaturer: 3
Initialer: 0

Status: Färdigställda

Kuvertskapare:
Larsson, Susanna
126 East Lincoln Avenue
Rahway, NJ 07065
susanna.larsson@msd.com
IP-adress: 147.161.188.164

Spela in spårning

Status: Original
2026-09-28 09:37:14

Hållare: Larsson, Susanna
susanna.larsson@msd.com

Plats: DocuSign

Signeringshändelser	Signatur	Tidsstämpel
Tomas Täckström tomas.taeckstroem@msd.com Säkerhetsnivå: E-post, Kontoautentisering (obligatoriskt), Inloggning med SSO	Signed by Tomas Täckström Tomas Täckström I approve this document Sep 29, 2026 | 12:06:57 PM CEST 8E98B997716E4C8C94CD59F1B6998E4D Signaturantagande: Förvald stil Signatur-ID: 8E98B997-716E-4C8C-94CD-59F1B6998E4D Med IP-adress: 166.49.179.162 Med signeringsautentisering via Docusign-lösenord Med Anledning till underskrift (på varje flik): I approve this document	Skickade: 2026-09-28 09:41:36 Visade: 2026-09-29 06:01:08 Signerade: 2026-09-29 06:07:16
Delgivande av elektronisk uppgift och signatur: Godkänt: 2026-09-29 06:01:08 ID: e3e7e258-7b26-42ab-8b34-620b68b91da7		
Niklas Lundblad niklas@mediahuset.se COO Niklas Lundblad Säkerhetsnivå: E-post, Kontoautentisering (obligatoriskt), Loggade in	Signed by Niklas Lundblad Niklas Lundblad Jag godkänner dokumentet Sep 29, 2026 | 5:23:36 AM MDT 3910D6124B644934BCDB709C3B14944D Signaturantagande: Förvald stil Signatur-ID: 3910D612-4B64-4934-BCDB-709C3B14944D Med IP-adress: 194.16.1.210 Med signeringsautentisering via Docusign-lösenord Med Anledning till underskrift (på varje flik): Jag godkänner dokumentet Jag godkänner dokumentet	Skickade: 2026-09-29 06:07:20 Visade: 2026-09-29 07:23:26 Signerade: 2026-09-29 07:24:09
Delgivande av elektronisk uppgift och signatur: Godkänt: 2026-09-29 07:23:26 ID: 7ccea804-5246-4b41-9ae8-217cede39a5b		

Händelser med undertecknare på plats	Signatur	Tidsstämpel

Redigerarleveranshändelser	Status	Tidsstämpel

Agentleveranshändelser	Status	Tidsstämpel

Mellanhandsleveranshändelser	Status	Tidsstämpel

Certifierade leveranshändelser	Status	Tidsstämpel

Kopieringshändelser	Status	Tidsstämpel
Eva Lindgren eva.lindgren@msd.com Säkerhetsnivå: E-post, Kontoautentisering (obligatoriskt) **Delgivande av elektronisk uppgift och signatur:** Erbjöds inte via Docusign	**Kopierad**	Skickade: 2026-09-29 07:24:12

Vittneshändelser	Signatur	Tidsstämpel

Notariehändelser	Signatur	Tidsstämpel

Sammanfattning av kuverthändelser	Status	Tidsstämplar
Kuvertet har skickats	Hashkodat/krypterat	2026-09-28 09:41:37
Certifierat levererat	Säkerhetskontrollerat	2026-09-29 07:23:26
Signeringen är slutförd	Säkerhetskontrollerat	2026-09-29 07:24:09
Färdigställda	Säkerhetskontrollerat	2026-09-29 07:24:12

Betalningshändelser	Status	Tidsstämplar

Delgivande av elektronisk uppgift och signatur

Delgivande av elektronisk uppgift och signatur skapat den: 2025-10-08 11:35:19
Parterna enades om: Tomas Täckström, Niklas Lundblad

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Merck & Co., Inc., Rahway, New Jersey, U.S.A. (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Merck & Co., Inc., Rahway, New Jersey, U.S.A.:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To advise Merck & Co., Inc., Rahway, New Jersey, U.S.A. of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Merck & Co., Inc., Rahway, New Jersey, U.S.A.

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to and in the body of such request you must state your email address, full name, mailing address, and telephone number.

To withdraw your consent with Merck & Co., Inc., Rahway, New Jersey, U.S.A.

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to ralph.grisi1@merck.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Merck & Co., Inc., Rahway, New Jersey, U.S.A. as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Merck & Co., Inc., Rahway, New Jersey, U.S.A. during the course of your relationship with Merck & Co., Inc., Rahway, New Jersey, U.S.A..